StoneWise Named 2026 Forbes China Industry Development Leader; Its Pharmaceutical R&D Agent Drives Industrial Value Transformation
On March 18, the 2026 New Era Brand Development Forum & Forbes China Industry Leader Awards Ceremony concluded successfully in Shanghai. Boasting cutting-edge proprietary technologies and scalable commercial capabilities, StoneWise was honored as a 2026 Forbes China Industry Development Leader — the only AI drug R&D company on the award list. This recognition validates our technological prowess and industrial value, and establishes StoneWise as a benchmark for integrated innovation across artificial intelligence and biopharmaceuticals.
Other awardees include UBTech, Haitian Flavouring & Food, Tide Pharmaceutical and Kunlun New Energy, leading enterprises across AI, consumer goods, healthcare and new energy sectors. All selected companies are widely acknowledged benchmarks with robust sustainable development capabilities.
Co-hosted by Forbes China and Frost & Sullivan, the selection framework evaluates candidates against five core metrics: alignment with national strategies, innovation capacity, business growth, sustainability and industrial influence, with a focus on industrial empowerment, operational performance and innovative practices.
Committed to deepening the integration of AI and biopharmaceuticals, StoneWise actively responds to national innovation-driven development strategies. We advance high-quality upgrading of the pharmaceutical sector via technological innovation and practice the mission of empowering the real economy with technology.
After rigorous data review, cross-industry evaluation and expert assessment, StoneWise stood out from numerous participants. The award fully recognizes our overall strengths in technological innovation, commercial implementation and industry impact, and affirms our position as a pacesetter in the AI drug R&D sector.
This achievement stems from our long-term commitment to technological innovation and proven track record in AI-driven drug research. Leveraging generative AI, StoneWise has developed a proprietary transferable and iterative multimodal AI 3D molecular generation foundation model. Supported by our in-house high-quality pharmaceutical datasets and a library of millions of virtual compounds, we deliver end-to-end new drug design solutions that combine computational and wet-lab approaches to accelerate early-stage pharmaceutical R&D.
To date, we have served over 100 research institutions and pharmaceutical companies worldwide, helping clients discover more than 20 early candidate drugs with differentiated mechanisms. Multiple projects have progressed to preclinical and clinical development phases.
To tackle core pain points in early pharmaceutical R&D, StoneWise has built a full-stack Pharmaceutical R&D Agent with leading-edge architecture, exclusive data assets and superior model performance. The system converts senior medicinal chemists’ decision-making logic into an AI-executable, optimizable and replicable workflow, creating a scalable, sustainable autopilot model for drug R&D.
Covering the full workflow from demand interpretation, R&D strategy planning, molecular design and assessment to experimental verification, our Agent accelerates R&D progress, cuts costs and improves output quality, delivering accessible intelligent solutions for global new drug development.
StoneWise has received a host of official and industry accolades over the years. We are certified as a National High-Tech Enterprise, a testament to our independent innovation strengths. In 2026, our joint laboratory with Peking University was accredited as the Beijing Key Laboratory for Intelligent Drug R&D, further consolidating industry-university-research collaboration.
We have also been featured on many renowned rankings, including CB Insights’ Active Chinese Biocomputing Enterprises in the Digital Economy Era, Top 10 Biomedicine Entities of the Zhongguancun International Frontier Tech Innovation Competition, and Top 100 China Digital Healthcare Companies (Future Healthcare 100).
Unyielded by market hype and short-term trends, StoneWise adheres to long-term development philosophy. We will continue to help domestic pharmaceutical firms break R&D bottlenecks, build technological moats and advance China’s biopharmaceutical industry to new heights of global innovation.
About StoneWise
Founded in 2018, StoneWise is a global leader in AI-powered innovative drug R&D.
We have developed the industry’s first end-to-end intelligent engine for new drug design, built around medicinal chemists’ decision-making workflows. Our proprietary multimodal AI 3D molecular generation foundation model, empowered by generative AI, features high transferability and iterative capability. Combined with a library of millions of virtual compounds, our integrated computational and wet-lab solutions streamline early drug R&D.
We provide molecular generation & design, custom model training, compound screening and other products and services to hundreds of pharmaceutical companies and research institutions globally. We also advance more than ten in-house drug development pipelines, several of which have entered clinical trials.
Contact Us
Business Cooperation: bd@stonewise.cn
Customer Support: support@stonewise.cn
Investor Relations: ir@stonewise.cn
Media Inquiries: pr@stonewise.cn
Customer Support: support@stonewise.cn
Investor Relations: ir@stonewise.cn
Media Inquiries: pr@stonewise.cn
